NCT07566156

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-05-11Est. Completion: 2030-03-31

Enrollment target: 390 participants

Locations

Samsun Clinic - Ridley-Tree Cancer Center, Santa Barbara, California, United States
Rocky Mountain Cancer Center, Aurora, Colorado, United States
Medical Oncology Hematology Consultants, Newark, Delaware, United States
Illinois Cancer Specialists, Niles, Illinois, United States
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
Missouri Cancer Associates, Columbia, Missouri, United States
Oncology Hematology Care Clinical Trials, LLC, Fairfield, Ohio, United States
Williamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States
Compass Oncology - West, Tigard, Oregon, United States
SCRI Oncology Partners, Nashville, Tennessee, United States
Texas Oncology, Austin, Texas, United States
Texas Oncology - Northeast Texas, Tyler, Texas, United States
Virginia Oncology Associates, Norfolk, Virginia, United States
Site CA01071, Montreal, Quebec, Canada

Metastatic Urothelial CarcinomaMetastatic Urothelial Carcinoma (UC)

A Randomized, Open-Label, Multicenter, Phase 2/3 Clinical Study of Ivonescimab in Combination with Enfortumab Vedotin vs…

Phoenix, United StatesEst. completion Oct 31, 2030

Bladder Cancer

Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments …

Washington D.C., United StatesEst. completion Jul 27, 2029

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.